AcousticaBio

AcousticaBio is an American preclinical biotechnology company focused on making biologic drug delivery simpler and more patient-friendly. Spun out of Harvard in 2022, the company describes itself as venture-backed and NIH-funded, and it has built collaborations with leading global biopharmaceutical companies on the strength of in-vitro and in-vivo safety and efficacy data. Its core proposition is to help drug developers reformulate new and existing biologic products into ultra-high-concentration subcutaneous injections, moving therapies that traditionally require lengthy hospital-based intravenous infusions into small-volume injections that can be administered outside infusion centers, including at home. The scientific foundation of AcousticaBio is a proprietary acoustophoretic fluid processing technology. The company states that it can create ultra-high concentrations of biologics exceeding 500 mg/mL, using microgel suspension formulations designed to reach optimal concentrations. This matters because monoclonal antibodies (mAbs) must be formulated at very high concentrations to enable small-volume subcutaneous dosing, yet at those levels mAbs often become highly viscous and unstable, making them difficult to manufacture, process, and inject. As a result, fewer than half of approved mAbs are available in subcutaneous form, typically limited to lower-dose products or those requiring large injection volumes. AcousticaBio positions its platform as a way to overcome that formulation bottleneck. The company argues that subcutaneous delivery benefits patients, drug developers, and the healthcare system alike. Patients generally prefer subcutaneous injections over IV infusions, and subcutaneous formulations can improve comfort and adherence while reducing the burden on clinics and care teams. For drug developers, the platform offers a route to differentiate products and extend life-cycle value by converting hospital-administered IV therapies into more convenient subcutaneous options. AcousticaBio is led by founder and CEO Daniele Foresti, who invented the company's fluid processing technology and earned a PhD in Mechanical Engineering from ETH Zürich. Professor Jennifer Lewis of the Harvard John A. Paulson School of Engineering and Applied Sciences is a scientific co-founder. The leadership team also includes Mike Hager as Director of Finance and Operations and Kristen Wek, Ph.D., as Senior Scientist. The company is privately held and venture-backed, with no public listing.

AcousticaBio was spun out of Harvard in 2022 as a venture-backed, NIH-funded preclinical biotechnology company. It was founded by Daniele Foresti, who invented the company's proprietary fluid processing technology and serves as founder and CEO, with Professor Jennifer Lewis of the Harvard John A. Paulson School of Engineering and Applied Sciences as scientific co-founder. The company's formation reflects a translation of academic research in acoustophoretic fluid handling into a commercial platform for biologic drug formulation and delivery. From its inception, AcousticaBio has focused on solving a central challenge in biologic drug delivery: enabling small-volume subcutaneous dosing of monoclonal antibodies and other biologics. Because mAbs must be formulated at very high concentrations for subcutaneous administration, and because they often become highly viscous and unstable at those concentrations, fewer than half of approved mAbs are available in subcutaneous form. The company's answer is a proprietary acoustophoretic technology that creates ultra-high concentrations of biologics exceeding 500 mg/mL, using microgel suspension formulations designed to achieve optimal concentrations. The company reports strong in-vitro and in-vivo safety and efficacy data and has built collaborations with leading global biopharmaceutical companies. Its stated mission is to bring life-saving drug delivery from the hospital to the home by converting lengthy hospital-based intravenous infusions into small-volume subcutaneous injections. AcousticaBio remains privately held and venture-backed, with no public listing, and continues to operate as a preclinical-stage platform company.

• 2022

  AcousticaBio spun out of Harvard as a venture-backed, NIH-funded preclinical biotechnology company.

• Company reports strong in-vitro and in-vivo safety and efficacy data and builds collaborations with leading global biopharmaceutical companies.

A preclinical biotechnology platform company enabling ultra-high-concentration subcutaneous biologic delivery by harnessing the precision of sound, aiming to move therapies from hospital IV infusion to patient-friendly injection.

• Acoustophoretic fluid processing platform

  Proprietary technology that creates ultra-high concentrations of biologics exceeding 500 mg/mL using microgel suspension formulations.

• Ultra-high-concentration subcutaneous formulations

  Formulations designed to enable small-volume subcutaneous injection of monoclonal antibodies and other biologics traditionally given by IV infusion.

1. 1AcousticaBio | Ultra-High Concentration Antibody Formulationsacoustica.bio
2. 2About Us | AcousticaBioacoustica.bio
3. 3AcousticaBiowikidata.org